27 February 2025
EMA/CHMP/62534/2025
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion[1] (post authorisation)

Ixchiq

chikungunya vaccine (live)

On 27 February 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Ixchiq. The marketing authorisation holder for this medicinal product is Valneva Austria GmbH.

The CHMP adopted an extension to the existing indication to include active immunisation of children from 12 years of age. The indication for Ixchiq will therefore be as follows:[2]

> IXCHIQ is indicated for active immunisation for the prevention of disease caused by chikungunya virus (CHIKV) in individuals ~~18~~ **12** years and older.
>
> The use of this vaccine should be in accordance with official recommendations.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

[1] Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion
[2] New text in bold, removed text as strikethrough

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union